Tharimmune (NASDAQ:THAR) Trading Up 3% – Should You Buy?

Tharimmune, Inc. (NASDAQ:THAR) shares were up 3% during mid-day trading on Thursday . The company traded as high as $2.11 and last traded at $2.06. Approximately 11,683 shares traded hands during trading, a decline of 71% from the average daily volume of 40,766 shares. The stock had previously closed at $2.00.

Analyst Ratings Changes

A number of research firms recently commented on THAR. RODMAN&RENSHAW upgraded Tharimmune to a “strong-buy” rating in a report on Friday, December 6th. Rodman & Renshaw began coverage on Tharimmune in a research report on Friday, December 6th. They set a “buy” rating and a $17.00 price objective for the company.

Tharimmune Trading Down 4.4 %

The business’s fifty day moving average is $2.09 and its two-hundred day moving average is $2.44.

Tharimmune (NASDAQ:THAR) last released its quarterly earnings results on Thursday, November 7th. The company reported ($2.45) EPS for the quarter.

Hedge Funds Weigh In On Tharimmune

An institutional investor recently bought a new position in Tharimmune stock. Curi RMB Capital LLC bought a new position in shares of Tharimmune, Inc. (NASDAQ:THAR) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 23,620 shares of the company’s stock, valued at approximately $59,000. Curi RMB Capital LLC owned approximately 2.06% of Tharimmune as of its most recent filing with the Securities and Exchange Commission (SEC). 1.16% of the stock is currently owned by institutional investors and hedge funds.

About Tharimmune

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).